Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

Company Calls Off Inhaled Remdesivir Program

 
• By Alaric DeArment
  
earnings report
Gilead reported in its second quarter 2021 earnings that its HIV business was showing signs of recovery from its pandemic-induced decline • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business